Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.36 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TAS2R31 | P59538 | 2/20 | 0.30 |
| ▸ | TAS2R46 | P59540 | 2/20 | 0.30 |
| ▸ | TAS2R10 | Q9NYW0 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494186 | 0.71 | ATM (1.00) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL29363077 | 0.71 | ATM (1.00) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL20877882 | 0.60 | ICAM1 (0.52) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL29694449 | 0.59 | ATM (0.67) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL31058464 | 0.57 | ATM (0.51) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL30613096 | 0.57 | CYP19A1 (0.57) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL23007994 | 0.56 | ICAM1 (0.44) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL21475309 | 0.56 | ICAM1 (0.44) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL21475315 | 0.56 | ICAM1 (0.44) | ATMCYP19A1RECQLCYP3A4ICAM1 | |
| SCHEMBL29398705 | 0.56 | CYP3A4 (0.53) | ATMCYP19A1RECQLCYP3A4ICAM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4583889-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | Iovance Biotherapeutics, Inc. (US) | 2025-07-16 | — | — | EP | claimed |
| WO-2025067472-A1 | METHODS OF CULTURING GAMMA DELTA T CELLS | NANJING LEGEND BIOTECH CO., LTD. (CN) | 2025-04-03 | — | — | WO | claimed |
| WO-2025015318-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2025-01-16 | — | — | WO | claimed |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. | 2025-01-02 | — | — | US | claimed |
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2024-11-07 | — | — | US | claimed |
| EP-4404969-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2024-07-31 | — | — | EP | claimed |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS INC (US) | 2024-06-13 | — | — | US | claimed |
| US-11981921-B2 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-05-14 | — | — | US | claimed |
| WO-2024055017-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2024-03-14 | — | — | WO | claimed |
| EP-4308691-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | Iovance Biotherapeutics, Inc. (US) | 2024-01-24 | — | — | EP | claimed |
| US-20230416680-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IOVANCE BIOTHERAPEUTICS, INC. | 2023-12-28 | — | — | US | claimed |
| WO-2023049862-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2023-03-30 | — | — | WO | claimed |
| WO-2022198141-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | claimed |
| EP-4743565-A2 | CYTOKINE ENCODING LENTIVIRAL VECTORS AND USES THEREOF FOR MAKING TUMOR INFILTRATING LYMPHOCYTES | Iovance Biotherapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| US-20260061052-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | IOVANCE BIOTHERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| WO-2025240673-A1 | CANCER TREATMENT USING AKT INHIBITORS AND PLK1 INHIBITORS | CARDIFF ONCOLOGY, INC. (US) | 2025-11-20 | — | — | WO | disclosed |
| WO-2022204565-A1 | COMBINATIONS COMPRISING ANTI-TM4SF1 ANTIBODIES AND IMMUNOTHERAPEUTIC AGENTS AND METHODS OF USING THE SAME | ANGIEX, INC. (US) | 2022-09-29 | — | — | WO | disclosed |
| WO-2022198141-A1 | METHODS FOR TUMOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | IOVANCE BIOTHERAPEUTICS, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| CN-114457157-A | PDE1A for tumor treatment target and diagnosis biomarker, kit and application | 浙大城市学院 | 2022-05-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240368547-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | ATM 614/4885CYP19A1 4339/4885RECQL 1356/4885 |
| US-20240191191-A1 | METHODS FOR INFILTRATING LYMPHOCYTE (TIL) EXPANSION RELATED TO CD39/CD69 SELECTION AND GENE KNOCKOUT IN TILS | CD69, CD209, ICOS | ATM 1331/4885CYP19A1 2779/4885RECQL 4779/4885 |
| US-20250000903-A1 | EXPANSION PROCESSES AND AGENTS FOR TUMOR INFILTRATING LYMPHOCYTES | NFATC1, MKI67, ICOS | ATM 1271/4885CYP19A1 3129/4885RECQL 4505/4885 |
| US-11981921-B2 | TIL expansion processes using specific cytokine combinations and/or AKTi treatment | IL15, IL15RA, ICOS | ATM 614/4885CYP19A1 4339/4885RECQL 1356/4885 |
| US-20230416680-A1 | TIL EXPANSION PROCESSES USING SPECIFIC CYTOKINE COMBINATIONS AND/OR AKTI TREATMENT | IL15, IL15RA, ICOS | ATM 614/4885CYP19A1 4339/4885RECQL 1356/4885 |
| US-20260061052-A1 | PROCESSES FOR GENERATING TIL PRODUCTS USING PD-1/TIGIT TALEN DOUBLE KNOCKDOWN | IL15, IL2, IL15RA | ATM 1729/4885CYP19A1 3912/4885RECQL 2859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.